Abstract：Objective To analyze the clinical effect of Tansoloxin and Levofloxacin in the treatment of chronic prostatitis. Methods From April 2017 to May 2020, 86 patients with chronic prostatitis were divided into control group and observation group according to the treatment plan, with 43 cases in each group. The control group was treated with Levofloxacin, the observation group was treated with Tansororosin and Levofloxacin. The clinical effect of two groups after treatment was analyzed. Results After three weeks of treatment, the total effective rate in the observation group was higher than that in the control group (P ＜ 0.05). There were no significant differences in interleukin (IL)-2, IL-6, macrophage inflammatory protein-2 (MIP-2), macrophage inflammatory protein-1α (MIP-1), leukocyte and lecithin corpuscles between the two groups before treatment (P ＞ 0.05). After three weeks of treatment the lecithin bodies in prostate fluid in the two groups increased, IL-2, IL-6, MIP-2, MIP-1α and white blood cells decreased compared with those before treatment, and the lecithin bodies in prostate fluid in the observation group were higher than those in the control group, and the inflammatory factors and white blood cells were lower than those in the control group (P ＜ 0.05). There was no significant difference in national institutes of health chronic prostatitis index (NIH-CPSI) score between the two groups before treatment (P ＞ 0.05). The pain, voiding symptoms, quality of life and total score of NIH-CPSI in the two groups decreased compared with before treatment, and those in the observation group were lower than the control group (P ＜ 0.05). Conclusion Tansoloxin combined with Levofloxacin in the treatment of chronic prostatitis can reduce inflammation, improve symptoms and improve the curative effect.
京公网安备 11010502046598号